Not all patients respond equally well to treatment. Here is the link to the clinical trajectories paper identifying three distinct trajectories for early seropositive rheumatoid arthritis patients.
RA-MAP Consortium, 2021. Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. Therapeutic advances in musculoskeletal disease, 13, p.1759720X211043977. https://doi.org/10.1177/1759720X211043977
No comments:
Post a Comment
Note: only a member of this blog may post a comment.